全文获取类型
收费全文 | 18751篇 |
免费 | 1180篇 |
国内免费 | 90篇 |
专业分类
耳鼻咽喉 | 173篇 |
儿科学 | 256篇 |
妇产科学 | 205篇 |
基础医学 | 2576篇 |
口腔科学 | 653篇 |
临床医学 | 1777篇 |
内科学 | 3954篇 |
皮肤病学 | 518篇 |
神经病学 | 1997篇 |
特种医学 | 1221篇 |
外科学 | 3037篇 |
综合类 | 90篇 |
一般理论 | 6篇 |
预防医学 | 884篇 |
眼科学 | 378篇 |
药学 | 990篇 |
中国医学 | 51篇 |
肿瘤学 | 1255篇 |
出版年
2024年 | 15篇 |
2023年 | 139篇 |
2022年 | 283篇 |
2021年 | 533篇 |
2020年 | 355篇 |
2019年 | 424篇 |
2018年 | 538篇 |
2017年 | 436篇 |
2016年 | 587篇 |
2015年 | 662篇 |
2014年 | 804篇 |
2013年 | 1010篇 |
2012年 | 1579篇 |
2011年 | 1482篇 |
2010年 | 922篇 |
2009年 | 800篇 |
2008年 | 1316篇 |
2007年 | 1409篇 |
2006年 | 1304篇 |
2005年 | 1216篇 |
2004年 | 1093篇 |
2003年 | 992篇 |
2002年 | 874篇 |
2001年 | 169篇 |
2000年 | 107篇 |
1999年 | 164篇 |
1998年 | 156篇 |
1997年 | 135篇 |
1996年 | 80篇 |
1995年 | 52篇 |
1994年 | 41篇 |
1993年 | 45篇 |
1992年 | 43篇 |
1991年 | 22篇 |
1990年 | 20篇 |
1989年 | 20篇 |
1988年 | 24篇 |
1987年 | 14篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 6篇 |
1982年 | 15篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1977年 | 7篇 |
1976年 | 5篇 |
1974年 | 7篇 |
1973年 | 11篇 |
1970年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
161.
Julian Marcon Matthias Trottmann Severin Rodler Armin J. Becker Christian G. Stief Ricarda M. Bauer Jozefina Casuscelli 《Andrologia》2021,53(1):e13881
We longitudinally assessed erectile function as well as the willingness to use pro-erectile treatment in a cohort on AAT for advanced RCC. Thirty-seven patients with advanced RCC completed the five-item version of the International Index of Erectile Function (IIEF-5) and other interview items before (T0) and 12 weeks into therapy (T12) with AAT. Patients were further asked if they were willing to use and pay out-of-pocket for on-demand treatment with phosphodiesterase-5-inhibitors (PDE-5i). Statistical analysis was performed using nonparametric hypothesis testing. The IIEF-5 score at T12 was significantly decreased compared with T0 (p < .001). Subjective patient satisfaction regarding their sexual lives was associated with higher IIEF-5 scores at both time points (p = .006 and p = .03, respectively). At T12, subjective sexual contentment showed a nonsignificant trend towards decline (p = .074). Patients who opted for medical treatment of ED showed significantly better IIEF-5 scores at both time points compared with the rest of the cohort (p < .001 and p = .005, respectively). In summary, AAT seems to have a negative effect on erectile function in RCC patients, however, the role of psychosocial issues warrants further elucidation. Affected patients may benefit from a proactive approach promoting medical treatment of erectile dysfunction during AAT. 相似文献
162.
Matthias Meyer Lukas Parik Felix Greimel Tobias Renkawitz Joachim Grifka Markus Weber 《The Journal of arthroplasty》2021,36(5):1533-1542
BackgroundModels for risk stratification and prediction of outcome, such as the Charlson Comorbidity Index (CCI), the Elixhauser Comorbidity Method (ECM), the 5-factor modified Frailty Index (mFI-5), and the Hospital Frailty Risk Score (HFRS) have been validated in orthopedic surgery. The aim of this study is to compare the predictive power of these models in total hip and knee replacement.MethodsIn a retrospective analysis of 8250 patients who had undergone total joint replacement between 2011 and 2019, CCI, ECM, mFI-5, and HFRS were calculated for each patient. Receiver operating characteristic curve plots were generated and the area under the curve (AUC) was compared between each score with regard to adverse events such as transfusion, surgical, medical, and other complications. Multivariate logistic regression models were used to assess the relationship among risk stratification models, demographic factors, and postoperative adverse events.ResultsIn prediction of surgical complications, HFRS performed best (AUC: 0.719, P < .001), followed by ECM (AUC: 0.578, P < .001), mFI-5 (AUC: 0.564, P = .003), and CCI (AUC: 0.555, P = .012). With regard to medical complications, other complications, and transfusion, HFRS also was superior to ECM, mFI-5, and CCI. Multivariate logistic regression analyses revealed HFRS as an independent risk stratification model associated with all captured adverse events (P ≤ .001).ConclusionThe HFRS is superior to current risk stratification models in the context of total joint replacement. As the HRFS derives from routinely collected administrative data, healthcare providers can identify at-risk patients without additional effort or expense. 相似文献
163.
Matthias Lngin Bruno Reichart Stig Steen Trygve Sjberg Audrius Paskevicius Qiuming Liao Guangqi Qin Maren Mokelke Tanja Mayr Julia Radan Lara Issl Ines Buttgereit Jiawei Ying Ann Kathrin Fresch Alessandro Panelli Stefanie Egerer Andrea Bhr Barbara Kessler Anastasia Milusev Riccardo Sfriso Robert Rieben David Ayares Peter J. Murray Reinhard Ellgass Christoph Walz Nikolai Klymiuk Eckhard Wolf Jan‐Michael Abicht Paolo Brenner 《Xenotransplantation》2021,28(1):e12636
164.
Eva Schrezenmeier Lukas J. Lehner Marina Merkel Manuel Mayrdorfer Wiebke Duettmann Marcel G. Naik Felix Fröhlich Lutz Liefeldt Mareen Pigorsch Frank Friedersdorff Danilo Schmidt Matthias Niemann Nils Lachmann Klemens Budde Fabian Halleck 《Transplant international》2021,34(4):732-742
The number of patients returning to dialysis after graft failure increases. Surprisingly, little is known about the clinical and immunological outcomes of this cohort. We retrospectively analyzed 254 patients after kidney allograft loss between 1997 and 2017 and report clinical outcomes such as mortality, relisting, retransplantations, transplant nephrectomies, and immunization status. Of the 254 patients, 49% had died 5 years after graft loss, while 27% were relisted, 14% were on dialysis and not relisted, and only 11% were retransplanted 5 years after graft loss. In the complete observational period, 111/254 (43.7%) patients were relisted. Of these, 72.1% of patients were under 55 years of age at time of graft loss and only 13.5% of patients were ≥65 years. Age at graft loss was associated with relisting in a logistic regression analysis. In the complete observational period, 42 patients (16.5%) were retransplanted. Only 4 of those (9.5%) were ≥65 years at time of graft loss. Nephrectomy had no impact on survival, relisting, or development of dnDSA. Patients after allograft loss have a high overall mortality. Immunization contributes to long waiting times. Only a very limited number of patients are retransplanted especially when ≥65 years at time of graft loss. 相似文献
165.
Teresa Rodriguez-Calvo Lars Krogvold Natalie Amirian Knut Dahl-Jrgensen Matthias von Herrath 《Diabetes》2021,70(3):752
In type 1 diabetes (T1D), a lifelong autoimmune disease, T cells infiltrate the islets and the exocrine pancreas in high numbers. CD8+ T cells are the main cell type found in the insulitic lesion, and CD8+ T cells reactive against β-cell antigens have been detected in peripheral blood and in the pancreas of patients with short- or long-term disease. In the Diabetes Virus Detection (DiViD) study, researchers collected pancreatic tissue, by pancreatic tail resection, from living patients with recent-onset T1D. These tissues have been extensively studied by the scientific community, but the autoreactive nature of the T-cell infiltrate has remained unexplored. Our objective was to determine the number and localization of these cells in pancreas samples obtained through the DiViD study. Here, we demonstrate the presence of high frequencies of CD8+ T cells reactive against a highly relevant epitope derived from the preproinsulin signal peptide in pancreatic tissue samples from these donors. We also show the heterogeneity of islet distribution and CD8+ T-cell infiltration. Our findings contribute to the current limited existing knowledge of T-cell reactivity in the pancreas of donors with recent-onset T1D and indicate that antigen-specific therapies directed toward preproinsulin could have high clinical impact. 相似文献
166.
167.
Burkhard Tönshoff Helio Tedesco-Silva Robert Ettenger Martin Christian Anna Bjerre Luca Dello Strologo Stephen D. Marks Lars Pape Udaykiran Veldandi Patricia Lopez Marc Cousin Priti Pandey Matthias Meier 《American journal of transplantation》2021,21(1):123-137
CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 36 was 9.8% vs 9.6% (difference: 0.2%; 80% confidence interval: −7.3 to 7.7) for EVR + rTAC and MMF + sTAC, respectively, which was driven by BPARs. Graft loss was low (2.1% vs 3.8%) with no deaths. Mean estimated glomerular filtration rate at month 36 was comparable between groups (68.1 vs 67.3 mL/min/1.73 m2). Mean changes (z-score) in height (0.72 vs 0.39; P = .158) and weight (0.61 vs 0.82; P = .453) from randomization to month 36 were comparable, whereas growth in prepubertal patients on EVR + rTAC was better (P = .050) vs MMF + sTAC. The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE-related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients. ClinicalTrials.gov: NCT01544491. 相似文献
168.
Diana Lüftner Andreas D. Hartkopf Michael P. Lux Friedrich Overkamp Hans Tesch Adriana Titzmann Patrik Pschke Markus Wallwiener Volkmar Müller Matthias W. Beckmann Erik Belleville Wolfgang Janni Tanja N. Fehm Hans-Christian Kolberg Johannes Ettl Diethelm Wallwiener Andreas Schneeweiss Sara Y. Brucker Peter A. Fasching 《Breast care (Basel, Switzerland)》2021,16(2):108
BackgroundThe therapeutic armamentarium for patients with metastatic breast cancer is becoming more and more specific. Recommendations from clinical trials are not available for all treatment situations and patient subgroups, and it is therefore important to collect real-world data.SummaryTo develop recommendations for up-to-date treatments and participation in clinical trials for patients with metastatic breast cancer, the Prospective Academic Translational Research PRAEGNANT Network was established to optimize the quality of oncological care in the advanced therapeutic setting. The main aim of PRAEGNANT is to systematically record medical care for patients with metastatic breast cancer in the real-life setting, including the outcome and side effects of different treatment strategies, to monitor quality-of-life changes during therapy, to identify patients eligible for participation in clinical studies, and to allow targeted therapies based on the molecular structures of breast carcinomas.Key MessagesThis article describes the PRAEGNANT network and sheds light on the question of whether the various end points from clinical trials can be transferred to the real-world treatment situation. 相似文献
169.
170.
Lorente Nicolas Sherriff Nigel Panochenko Oksana Marcus Ulrich Dutarte Maria Kuske Matthias Aussó Susanna Huber Jörg Krone Michael Schink Susanne Barbara Cawley Caoimhe Casabona Jordi Folch Cinta 《Journal of community health》2021,46(3):545-556
Journal of Community Health - Little is known about Community Health Workers (CHWs) who work in non-clinical settings to provide sexual health support around HIV, viral hepatitis, and other... 相似文献